Decoy20

Decoy20 is an attenuated, killed, non-pathogenic bacterial product derived from a K-12 strain of Escherichia coli. It is engineered to have approximately 90% reduced lipopolysaccharide (LPS)-endotoxin activity to enhance intravenous safety while retaining endogenous agonist activity for multiple innate immune receptors including Toll-like receptors (TLR1/2, TLR2/6, TLR8, TLR9), NOD2, and STING. The drug is designed to activate both the innate and adaptive immune systems by inducing transient systemic immune activation and broad immune cell trafficking. Preclinical studies demonstrated single-agent and combination-mediated anti-tumor activity in models of colorectal cancer, hepatocellular carcinoma, pancreatic adenocarcinoma, non-Hodgkin's lymphoma and other solid tumors. In clinical trials it has been evaluated as monotherapy or in combination with checkpoint inhibitors such as tislelizumab for patients with advanced/metastatic solid tumors refractory to standard therapy. Developed by Indaptus Therapeutics, Decoy20 is being developed primarily for use in oncology as an immunotherapy platform that can be used alone or in combination with other agents such as PD-1 inhibitors. Its mechanism leverages transient but broad activation of the immune system through multiple pattern recognition receptors.